Rubicon Research Q1 FY27: Growth, Margins, and the Next Manufacturing Leg

Revenue from operations was INR 5,343 million, EBITDA was INR 1,312 million, and PAT was INR 848 million, with YoY growth of 51.6%, 64.6%, and 95.8% respectively.

Management stated Arinna contributed about INR 128 million (around INR 12 crore) of revenue in Q1 FY27 and the EBITDA contribution was not material.

Management revised guidance upward and stated that for FY27 as a whole, operating EBITDA margins would hold at least 23%.

The company stated it is on track to ramp up commercial operations at Pithampur from Q1 calendar year 2027.

Rubicon acquired the US FDA-inspected facility for USD 2.9 million. The site is expected to be commercialized in CY2027 after implementing Rubicon’s quality management systems, focusing on specialty and high-value products and potential US government demand.

Management reiterated guidance of INR 5,000 million plus R&D spend over FY26, FY27 and Q1 FY28, fully expensed through the P&L.

The company reported 86 active approved products as of 30 June 2026 and said 76 of 86 were commercialized, implying an 88% commercialization rate.